Year-over-year earnings per share growth for the last twelve months: vynetherapeutics.com (VYNE)

VYNE Therapeutics Inc. - graphic logo of issuer VYNE

The innovative vector of VYNE Therapeutics (VYNE) focuses on developing selective BET inhibitors for the treatment of skin inflammation. The operating model relies on extensive outsourcing of synthesis and testing through external vendors. Relative quarterly EPS dynamics demonstrate the company's resilience, where the value of 58.80 serves as the baseline indicator. Management's strategic course is aimed at the commercialization of unique topical treatments within narrow medical niches.

VYNE: VYNE Therapeutics, Inc. Year-over-year earnings per share growth for the last twelve months 07/04/2022 - 07/28/2026

Comprehensive metric breakdowns and analytics for vynetherapeutics.com (VYNE)

- share price and expert price forecast:
- company stock exchange capitalization indicators:
Comprehensive company analysis:vynetherapeutics.com, VYNE
Manufactured product of VYNE Therapeutics

The high scalability of VYNE Therapeutics (VYNE) dermatological patents, coupled with minimal production costs, provides potential for explosive market capitalization growth. Analyzing quarterly earnings per share dynamics, an investor can observe the daily updated growth rate of net income, which serves as the basis for calculating alpha and determining the asset's fair value within the current sideways range.

Who VYNE Therapeutics competes with

KRYS: Quarterly EPS earnings growth|APGE - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Arcutis Biotherapeutics, Inc.|Year-over-year earnings per share growth for the last 12 months VCEL (Vericel)|Year-over-year earnings per share growth for the last twelve months Oruka Pharma (ORKA)|Year-over-year net earnings per share change for the last twelve months Sanara MedTech|Quarterly EPS earnings growth DBVT (DBV Technologies SA)|Solesence Inc (SLSN) - Earnings per share growth in annualized terms for the last twelve months|DERM: Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months FBRX (Forte Biosciences)|Empro Group (EMPG) - Year-over-year earnings per share growth for the last twelve months|Net earnings per share growth for the trailing year Sol-Gel Technologies Ltd. SLGL|Year-over-year net earnings per share growth for the last 12 months AXIL|Year-over-year net earnings per share growth for the last 12 months Medicus Pharma Ltd. (MDCX)|Quarterly EPS earnings growth VRCA|Year-over-year earnings per share growth rate for the last twelve months HOTH|Year-over-year earnings per share growth for the last twelve months biofrontera-us.com BFRI|Year-over-year earnings per one share growth for the last 12 months SNOA|Quoin Pharmaceuticals Ltd. - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months Azitra Corporation AZTR|DRMA (Dermata) - Year-over-year net earnings per share growth for the last 12 months|Elevai Labs Inc. (ELAB) - Quarterly EPS earnings growth|RVNC (Revance Therapeutics, Inc.) - Quarterly EPS earnings growth